Elicio Therapeutics (ELTX) announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma . The multi-center investigator-initiated trial will be led by principal investigator, Kevin Soares, M.D., from Memorial Sloan Kettering Cancer Center, and is being funded by the Lustgarten Foundation. The IIT will evaluate mFOLFIRINOX in combination with ELI-002 7P, with or without the anti-PD-1 antibody. The study is designed to enroll 20 patients across two cohorts. The trial is expected to commence in H1’2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELTX:
- Elicio Therapeutics reports inducement grants
- Elicio Therapeutics Announces Promising Phase 2 Vaccine Results
- Elicio reports ELI-002 7P induced T cell responses in 99% of patients
- Elicio Therapeutics Publishes Promising Phase 1 Study Data
- Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 data